201849-21-0

Basic information

• Product Name: 2-(4'-BROMO-2'-CHLOROPHENOXY)PROPANE
• Synonyms: 2-(4'-BROMO-2'-CHLOROPHENOXY)PROPANE;4-BROMO-2-CHLORO-1-ISOPROPOXYBENZENE;4-bromo-2-chloro-1-propan-2-yloxybenzene
• CAS NO: 201849-21-0
• Molecular Formula: C₉H₁₀BrClO
• Molecular Weight: 249.53
• Mol File: 201849-21-0.mol

Chemical Properties

• Boiling Point: 269.5±20.0 °C(Predicted)
• Appearance: /
• Density: 1.426±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-(4'-BROMO-2'-CHLOROPHENOXY)PROPANE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4'-BROMO-2'-CHLOROPHENOXY)PROPANE(201849-21-0)
• EPA Substance Registry System: 2-(4'-BROMO-2'-CHLOROPHENOXY)PROPANE(201849-21-0)

Safety Data

• Hazardous Substances Data: 201849-21-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4'-BROMO-2'-CHLOROPHENOXY)PROPANE is used as a chemical intermediate for the synthesis of pharmaceuticals, contributing to the development of new medications.
Used in Agrochemical Industry:
2-(4'-BROMO-2'-CHLOROPHENOXY)PROPANE is used as a chemical intermediate in the production of agrochemicals, specifically in the creation of pesticides and herbicides, to enhance crop protection and yield.
Used in Organic Synthesis:
2-(4'-BROMO-2'-CHLOROPHENOXY)PROPANE is utilized as a reagent in organic synthesis, playing a crucial role in the formation of complex organic molecules for various applications.

Upstream product

• 75-30-9 2-iodo-propane 
• 3964-56-5 4-bromo-2-chlorophenol 
• 75-26-3 isopropyl bromide 

Downstream Products

• 1344997-80-3 methyl 1-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]ethyl}-3-azetidinecarboxylate 
• 1344997-79-0 ethyl 1-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]ethyl}-4-piperidinecarboxylate 
• 1344997-78-9 methyl 1-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]methyl}-3-azetidinecarboxylate 
• 1344997-75-6 ethyl 1-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]methyl}-4-piperidinecarboxylate 
• 1344997-72-3 methyl 1-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-5-fluoro-2-(methyloxy)phenyl]ethyl}-3-azetidinecarboxylate 
• 1344997-70-1 [3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-5-fluoro-2-(methyloxy)phenyl]acetaldehyde 
• 1344997-69-8 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-{5-fluoro-2-(methyloxy)-3-[(E)-2-(methyloxy)ethenyl]phenyl}-1,3-thiazole 
• 1260024-00-7 [3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] acetaldehyde 
• 1260023-98-0 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-1,3-thiazole 
• 1260023-93-5 3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylbenzaldehyde 
• 1258440-40-2 5-bromo-2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazole 
• 1258440-38-8 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazole 
• 1334607-75-8 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoic acid 
• 1334608-21-7 ethyl 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoate 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as a sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as sphingosine 1- phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS

Compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by S1P1 receptors.

5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS

5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.